More on the Impact of the FDA RIFs: How Information Disclosure will Start FOIA-lling Behind
FDA Law Blog: Biosimilars
APRIL 10, 2025
While much of the focus has been on how these cuts may impact application review timelines and industry engagement, see earlier post about the effect on generic drugs, another quieter consequence is emerging a significant slowdown in the availability of information that FDA is required to produce under the Freedom of Information Act (FOIA).
Let's personalize your content